From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis
Abstract Therapy for relapsing–remitting multiple sclerosis (MS) has advanced dramatically despite incomplete understanding of the cause of the condition. Current treatment involves inducing broad effects on immune cell populations with consequent off‐target side effects, and no treatment can comple...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Clinical & Translational Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1002/cti2.1437 |